HBOT, Mitochondria & Oxidative Stress: What Does the Evidence Say?

Key Message

This review highlights: Short-term HBOT exposure can increase mitochondrial stress and ROS; however, longer-term or intermittent protocols improve mitochondrial function and reduce ROS. This occurs via upregulation of antioxidant systems (SOD, catalase/GPx) and activation of Nrf2, SIRT1, and HIF-1α (the hyperoxic–hypoxic paradox). These mechanisms explain why HBOT may be therapeutically relevant in conditions with mitochondrial dysfunction. (PubMedDOI)

Content in Brief (plain language)

How HBOT Affects Mitochondria

• Oxygen supply boost: HBOT increases dissolved oxygen in tissues (up to ~20-fold at ~2.5 ATA). Mitochondria are the main target organelles.

Dual Effect on ROS

• Short-term: Possible increase in ROS/oxidative stress.

• Long-term/intermittent: Enhanced antioxidant capacity, lower ROS levels, and improved mitochondrial performance.

Key Pathways & Defense Systems

• Antioxidant enzymes: SOD → H₂O₂ breakdown via catalase/GPx; in the brain, additional Trx/Prx systems.

• Transcriptional programs:

  • Nrf2: upregulates antioxidant genes.

  • SIRT1: promotes mitochondrial biogenesis.

  • HIF-1α: mimics hypoxia via intermittent hyperoxia.

Clinical Relevance (from the Review)

Many diseases involve mitochondrial dysfunction and ROS imbalance → HBOT provides a biologically plausible therapeutic pathway. (Review-level evidence, no new patient cohort).

Limitations of the Evidence

• Narrative review (no new clinical data).

• Heterogeneous primary study protocols (pressure, duration, cycles) → outcomes depend strongly on dose–time pattern.

FAQ Snippets (for your website)

Does oxidative stress increase under HBOT?

• Short-term: Yes, temporarily.

• Intermittent/longer-term: Adaptive responses dominate, with antioxidant upregulation → net ROS↓ and mitochondrial function↑.

Why is “intermittent” important?

• Repeated hyperoxia triggers hormetic signaling (Nrf2/SIRT1/HIF-1α) – the core of the hyperoxic–hypoxic paradox.